Approval · Notice of Compliance 14652 · 2013
SDZ-SUMATRIPTAN: Notice of Compliance 14652
Issued August 15, 2013
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 14652
- Date
- August 15, 2013
- Company
- Sandoz Canada Inc.Saint-Hubert, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Administrative additional product name
- Therapeutic class
- 5-ht1 receptor agonist; migraine therapy
- Canadian reference product
- IMITREX
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| SDZ-SUMATRIPTAN | 02409909 | Cancelled Pre Market |
| SDZ-SUMATRIPTAN | 02409917 | Cancelled Pre Market |
Medicinal ingredients
- SUMATRIPTAN SUCCINATE 50 MG per TAB
- SUMATRIPTAN SUCCINATE 100 MG per TAB